2004
DOI: 10.1093/humrep/deh263
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Metformin reduced development of GD, was not teratogenic and did not adversely affect birth length and weight, growth or motor-social development in the first 18 months of life.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

3
136
0
6

Year Published

2006
2006
2017
2017

Publication Types

Select...
4
3

Relationship

0
7

Authors

Journals

citations
Cited by 227 publications
(145 citation statements)
references
References 39 publications
3
136
0
6
Order By: Relevance
“…In contrast, the prevalence of large for gestational age births (LGA) were the same in both groups (27). On the other hand, others did or did not find a gender-specific decrease of birth weight in offspring of PCOS women (28,29).…”
Section: Discussionmentioning
confidence: 90%
“…In contrast, the prevalence of large for gestational age births (LGA) were the same in both groups (27). On the other hand, others did or did not find a gender-specific decrease of birth weight in offspring of PCOS women (28,29).…”
Section: Discussionmentioning
confidence: 90%
“…Of the 25 trials included for this review, there were four randomised controlled trials (RCTs) [10][11][12][13], one clinical trial [14], four retrospective cohort studies [15][16][17][18], and sixteen prospective cohort studies [19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34]. These studies were conducted globally with a large number originating from USA.…”
Section: Resultsmentioning
confidence: 99%
“…Women starting metformin in pregnancy were titrated up from half dose in the first week to full dose for the remainder of the pregnancy [11][12][13]. The maximum doses of metformin reached 2550 mg daily [19,22,24,28,30,[32][33][34]. The study design and outcomes of the RCTs are summarised in Table 1.…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations